Louisiana's Act 374 and Compounded Peptides: What Changed

On August 1, 2026, a two-paragraph addition to Louisiana law took effect. Act 374 created R.S. 37:23.5, and it does one narrow thing: it tells state professional and occupational licensing boards what they may not prohibit when it comes to peptides.

That is a smaller change than the attention around it suggests, and also a more interesting one. It does not declare any peptide safe or effective. It does not create a new federal pathway. It changes who gets to say no, and only in one state.

What the statute actually says

The enacted text is short enough to cover completely.

Subsection A provides that no professional or occupational licensing board shall prohibit a healthcare provider with prescriptive authority from providing patients with peptides shipped from either an FDA-registered 503B outsourcing facility that is in compliance with 21 U.S.C. 353b, or a 503A compounding pharmacy that is in compliance with 21 U.S.C. 353a and applicable United States Pharmacopeia-National Formulary chapters.

Subsection B provides that no such board shall prohibit a Louisiana-licensed pharmacist in a state-permitted pharmacy from compounding and dispensing peptides, so long as that pharmacist is in compliance with 21 U.S.C. 353a and applicable USP-NF chapters.

That is the whole operative law. There is no list of approved peptides, no registry, and no new enforcement body.

The bill was SB253, authored by Senator Patrick McMath. According to the legislature's official bill record, it passed the Senate 35-0 on March 23, 2026, passed the House 98-0 on May 7, 2026, was concurred in 37-0 on May 18, 2026, and was signed by the Governor on May 22, 2026 as Act No. 374, with an effective date of August 1, 2026. Those are unanimous recorded votes in both chambers.

The compliance conditions are doing the real work

The protection Act 374 grants is conditional. Strip out the "in compliance with" clauses and nothing is left, so it is worth understanding what those two federal sections require.

503A: traditional pharmacy compounding

Under 21 U.S.C. 353a, a compounded drug is exempt from three federal requirements: new drug approval, the requirement to bear adequate directions for use, and current good manufacturing practice standards. In exchange, several conditions have to hold. The drug must be compounded by a licensed pharmacist in a state-licensed pharmacy or by a licensed physician. It must be compounded for an identified individual patient based on a valid prescription order, though limited quantities may be prepared in advance where there is an established relationship and a history of valid orders.

The conditions on the ingredient itself are the ones most people miss. A bulk drug substance must comply with an applicable USP or National Formulary monograph if one exists, plus the USP chapter on pharmacy compounding. If no monograph exists, it must be a component of an FDA-approved drug. If neither applies, it must appear on a list developed by the Secretary. On top of that, the substance must be manufactured by an FDA-registered establishment, and valid certificates of analysis must be maintained for it.

That is a test applied to the specific substance, not to the pharmacy in general. A pharmacy can be fully compliant and still be unable to lawfully compound a given peptide, because the gate is at the ingredient.

503B: outsourcing facilities

Under 21 U.S.C. 353b, an outsourcing facility is a facility at one geographic location engaged in the compounding of sterile drugs that has registered with FDA as such. Compounding must occur by or under the direct supervision of a licensed pharmacist. The facility registers with FDA annually, reports the drugs it compounded twice a year, submits adverse event reports, labels its products as compounded drugs, and is subject to risk-based FDA inspection.

Two differences from 503A matter here. An outsourcing facility is not required to be a licensed pharmacy, and it may or may not hold prescriptions for identified individual patients. That is why 503B products can reach a prescriber's office in a way a patient-specific 503A preparation cannot.

A compounded drug under either section is exempt from FDA new drug approval. Exempt from approval is not the same as approved. Act 374 does not change that, and nothing in the statute speaks to whether any peptide is safe or works.

What Act 374 does not do

Being precise about the limits matters more here than usual, because the gap between what the law says and what people assume it says is wide.

• It does not touch federal law. Act 374 constrains Louisiana licensing boards. FDA's authority over compounded drugs is unchanged, and the statute is written to depend on federal compliance rather than displace it.
• It does not make any peptide FDA approved, or evaluated by FDA for safety or effectiveness.
• It says nothing about whether any peptide does anything. There is no clinical finding anywhere in the text. Questions about evidence for a specific peptide are entirely separate from questions about this law.
• It protects two channels and only two channels. Peptides sourced outside a compliant 503A pharmacy or a registered 503B facility, including research-use-only material and imported product, are outside what this statute addresses.
• It binds licensing boards. It is not a statement about insurance coverage, employer policy, sport or competition rules, or any other regulator.
• It is one state. As of August 14, 2026, this is Louisiana law and applies to Louisiana boards and Louisiana-licensed pharmacists.

If you are already using or considering a compounded peptide

The practical effect of Act 374 is on your prescriber and your pharmacist, not directly on you. It removes a specific category of professional risk they were carrying, which in some cases was the reason a clinician declined to have the conversation at all.

If that conversation is now open, the useful questions are the ones the statute itself points at. Which channel is this coming through, a 503A pharmacy or a 503B outsourcing facility? For a 503A preparation, does the specific substance satisfy the bulk drug substance conditions in 21 U.S.C. 353a, and are certificates of analysis on file? What is actually known about this compound in humans, and what is not?

Those are questions for a licensed provider who can look at your situation, not questions a law answers. And the honest limit on all of it: a statute that protects access says nothing about whether access is the right choice for any particular person. This article reports the legal status as of August 14, 2026 and is not legal advice. Legislation and board rules change.